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Abstract
DNA methylation and histone modifications are two major epigenetic events regulating gene expression and chromatin
structure, and their alterations are linked to human carcinogenesis. DNA methylation plays an important role in tumor
suppressor gene inactivation, and can be revised by DNA methylation inhibitors. The reversible nature of DNA methylation
forms the basis of epigenetic cancer therapy. However, it has been reported that DNA re-methylation and gene re-silencing
could occur after removal of demethylation treatment and this may significantly hamper the therapeutic value of DNA
methylation inhibitors. In this study we have provided detailed evidence demonstrating that mammalian cells possess a
bona fide DNA methylation recovery system. We have also shown that DNA methylation recovery was mediated by the
major human DNA methyltransferase, DNMT1. In addition, we found that H3K9-tri-methylation and H3K27-tri-methylation
were closely associated with this DNA methylation recovery. These persistent transcriptional repressive histone
modifications may have a crucial role in regulating DNMT1-mediated DNA methylation recovery. Our findings may have
important implications towards a better understanding of epigenetic regulation and future development of epigenetic
therapeutic intervention.
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Introduction
DNA methylation plays an important role in epigenetic
transcriptional control. In mammalian genome, DNA methylation
is established and maintained by the activity of DNA methyl-
transferases (DNMTs). DNMT3A and DNMT3B are known as de
novo methyltransferases and are able to transfer methyl groups to
unmethylated CpG dinucleotides [1,2]. Activation of DNMT3A
and DNMT3B during embryonic development establishes the
DNA methylation pattern, which is essential for cell fate
determination, as well as gene imprinting and X-chromosome
inactivation [3,4]. On the other hand, in somatic cells,
maintenance of DNA methylation during DNA replication is
carried out in a semi-conservative manner by the activity of
DNMT1, which shows a higher affinity to hemimethylated DNA
template and is physically associated with PCNA in the replication
fork [1,5]. This model provides a simple and elegant explanation
for the inheritability of DNA methylation information. Recently,
growing evidence has, however, indicated that the DNA
methylation machinery is in fact more complicated. For example,
it has been demonstrated that DNMTs physically bind to several
histone modifiers including histone deacetylases (HDACs) [6,7],
SUV39H1 [8] and EZH2 [9]. The formation of multi-component
epigenetic regulatory complex suggests that DNA methylation and
histone modification machineries function in a highly cooperative
manner in regulating chromatin structure and gene expression.
Epigenetic gene silencing, particularly DNA hypermethylation,
has been recognized as an alternative alteration besides mutations
and deletions in the ‘‘two hits’’ inactivation of tumor suppressor
genes. Epigenetic gene silencing is a reversible process. Numerous
studies have demonstrated that treatment of DNA methylation
inhibitors such as 5-Aza-deoxycytidine (5-Aza-dC) can robustly
reactivate the expression of epigenetically silenced tumor suppres-
sor genes [4]. These findings form the basis of the therapeutic use
of DNA methylation inhibitors, leading to the recent development
of epigenetic therapy in cancer treatment [10]. Theoretically,
pharmacologically demethylated CpG dinucleotides are inherit-
able and will be preserved upon DNA replication, unless
secondary de novo DNA methylation takes place [11,12]. Although
DNA re-methylation and gene re-silencing after 5-Aza-dC
treatment has been reported [12,13], a fundamental question
remains unanswered. This is because the DNA re-methylation
process reported could simply be due to a selection artifact caused
by the growth advantage of cells that were resistant to 5-Aza-dC
treatment or might have occasionally escaped from DNA
demethylation. Therefore, it is of crucial significance to investigate
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16702the detailed mechanisms of DNA re-methylation. Herein, we have
provided strong evidence to demonstrate that DNA methylation
recovery is a bona fide biological mechanism in mammalian cells
and have revealed the indispensable role of DNMT1 in this DNA
re-methylation. Our results also indicate that DNA methylation
recovery was closely associated with transcriptional repressive
H3K9 and H3K27 tri-methylations. These findings may have
important implications to a better understanding of epigenetic
regulation and future development of epigenetic therapeutic
intervention.
Materials and Methods
Cell lines and 5-Aza-dC treatment
Cancer cell lines used in this study were obtained from Shanghai
Institute of Cell Biology (SMMC-7721) or ATCC (HeLa). DNMT
knock-out cell lines (1KO, 3bKO and DKO) and their parental
HCT116 cells were kindly provided by Prof. B. Vogelstein, Johns
Hopkins University School of Medicine, Baltimore, MD [14,15].
SMMC-7721 and Hela cells were maintained in DMEM-high
glucose (Gibcol), supplemented with 10% FBS (Invitrogen).
Parental and DNMT KO HCT116 cell lines were grown in
McCoy 5A medium (Sigma) and supplemented with 10% FBS. 5-
Aza-dC (Sigma) was dissolved in 50% acetate and stored at -80uC
untiluse.For5-Aza-dCtreatment,3610
4cellswereseededonto60-
mmdishesand treatedwith 5-Aza-dCateither5 mM(HCT116 and
HeLa) or 10 mM (SMMC-7721) for 4 days. 5-Aza-dC was
replenished daily during the treatment. At Day 4, 5-Aza-dC was
removed from the culture, and 5-Aza-dC treated cells were washed
with PBS and allowed to recover in normal culture medium.
RNA extraction and RT-PCR
Total RNA was extracted by TRIZOL reagent, according to the
manufacturer’s instructions (Life Technologies). cDNA was synthe-
sized from 1 mg of total RNA by GeneAmp RNA PCR Kit with
random hexamer primers in a 20 mL reaction mixture (Applied
Biosystems). Semi-quantitative RT-PCR was carried out in 20 mL
reaction containing 1X PCR buffer, 1X CG RICH buffer (Roche),
0.8 mM dNTP, 2 mM MgCl2, 0.5 mM of each primers, 0.1U
AmpliTaq Gold and 2 mL ofcDNA (Applied Biosystems). The PCR
was terminated at the exponential phases: 30 cycles for DLC-1 and
18 cycles for GAPDH including one cycle of hot-start at 95uC for
12 min, followed by amplification at 94uC for 30 s, 55uC for 30 s,
72uC for 45 s, and a final extension at 72uC for 10 min.
Quantitative RT-PCR was carried out in 20 mL reaction mixture
containing 1X TaqMan Master mix, 1X gene-specific TaqMan
porbe and 1 mL cDNA. The PCR reactionwas performed withABI
7900HT system (Applied Biosystems) at the following conditions:
50uC for 2 min, 95uC for 10 min followed by 40 cycles of 95uC for
15 s, 60uC for 1 min. Gene expression was normalized against
endogenous control HPRT by DCt [Target – HPRT]. Relative gene
expression was determined by DDCt [Control – Test] and expressed
as fold change relative to the corresponding control sample
(i.e. 2
-.DDCt). PCR primers and TaqMan Probes used in this study
are listed in Table S1 and Figure S1.
Immunoblotting
Protein was extracted by NET-NP40 buffer in the presence of
Complete
TM Protease Inhibitor Cocktail (Roche). 20 mg of protein
was separated in 8% SDS-PAGE and transferred to PVDF
membrane (Amersham) for immunoblotting. The membrane was
probed by anti-DLC1 antibody (1:200, BD Biosciences) [16] and
b-actin (Sigma) followed by incubation with anti-mouse IgG (GE
Healthcare). Protein expression was detected with the ECL
TM
detection system (GE Healthcare) according to the manufacturer’s
protocol.
DNA extraction and methylation analysis
High-quality genomic DNA was extracted by phenol/chloro-
form after proteinase K treatment. Sodium bisulfite treatment was
carried out using the CpGenome DNA modification kit (Chemi-
con). Two mL of bisulfite treated DNA was amplified by PCR with
primers specific for methylated and unmethylated alleles of the
DLC-1 gene. Reaction were carried out at the following conditions:
hot start at 95uC for 12 min, followed by 32 cycles of 94uC for
30 s, 58uC for 30 s and 72uC for 30 s, and final extension at 72uC
for 10 min. Semi-quantitative analysis was performed by deter-
mining the band intensity using AlphaEaseFC software (Alpha
Innotech). For Pyrosequencing, 5 mL disfulite treated DNA first
amplified in a 50 mL reaction with CG RICH solution (Roche) at
the following PCR cycles: 95uC for 12 min, followed by 45 cycles
of 94uC for 30 s, 55uC for 30 s and 72uC for 30 s, and final
extension at 72uC for 10 min. Biotinated single strand PCR
product was purified with Streptavidin coated Sepharose beads
and subjected to Pyrosequencing in PyroMark ID system as
manufacture’s instruction (Biotage). Primer sequences are listed in
Table S1 and Figure S1.
Establishment of 5-Aza-dC-recovered clones
SMMC-7721 cells were treated with 5-Aza-dC as described
above. At Day 4, 5-Aza-dC treated cells were trypsinized, diluted,
plated onto 100-mm culture dishes and recovered in normal
culture medium for two weeks. Colonies formed by single 5-Aza-
dC-recovered clones were isolated from the culture dishes using a
Cloning cylinder (Bellco Biotechnology). The expression and
methylation level of hypermethylated genes were analyzed as
mentioned above.
Chromatin immunoprecipitation (ChIP) assay
2610
7 cells of each parental SMMC-7721 and its various derived
clones were used for ChIP assay. Chromatin was crosslinked with
formaldehyde and sonicated to an average size of 200–1000 bp.
ChIP assay was performed with EZ chromatin immunoprecipita-
tion kit according to the manufacturer’s protocol (Upstate
biotechnology, Lake Placid, NY). 1 mg of rabbit antibody against
tri-methylated H3K4, tri-methylated H3K9 and tri-methylated
H3K27, respectively, were mixed with sheared chromatin and
incubated at 4uC overnight. Chromatin-antibody complexes were
then precipitated with Salmon Sperm DNA/Protein A agarose.
Reagents and antibodies used in ChIP assay were obtained from
Upstate. Real-time PCR amplification was carried out with Power
SYBR Green PCR Master Mix according to manufacturer’s
instructions (Applied Biosystems, Foster City, CA). PCR cycles
are identical to the quantitative RT-PCR used for gene expression
analysis described above. Primer sequences are listed in Table S1
and Figure S1. Data are presented as ‘‘Relative enrichment’’ by the
equation 2
[DCt (No Antibody –Input) - DCt (Target – Input)].
Results
Restoration of DNA methylation after removal of
demethylating agent was a general phenomenon
In this study, first, we made use of the DNA demethylating
action of 5-Aza-dC to induce global DNA demethylation in a
hepatocellular carcinoma (HCC) cell line, SMMC-7721, and
investigated if the cells could restore their DNA methylation
information when the drug was removed (Fig. 1A). We found that
the cancer cells were able to restore their DNA methylation
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PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e16702information disturbed by 5-Aza-dC treatment. DLC1 (Deleted in
liver cancer 1), a hypermethylated tumor suppressor gene in
primary HCCs and in SMMC-7721 (Figure S2) [17], was
drastically re-expressed upon 5-Aza-dC treatment. However, this
re-expression rapidly disappeared once 5-Aza-dC was removed at
Day 4 (Fig. 1B and 1C). Concomitant with gene re-silencing,
DLC1 promoter gradually re-acquired its DNA methylation
(Fig. 1D). Similar gene re-silencing phenomenon was also observed
in other known hypermethylated tumor suppressor genes (E-
Cadherin and GSTP1), oncogenes (uPA) and tissue-specific genes
(KRT19) (Fig. 1E). In contrast and consistent with its unmethyla-
tion status, the expression level of tumor suppressor gene
p16
CDKN2A was not affected throughout the study (Fig. 1E). Apart
from SMMC-7721 HCC cell line, DNA re-methylation was also
consistently observed in other cancer cell lines, including HCT116
(Fig. 2) and HeLa (Figure S3), indicating that it was not a cell type-
specific phenomenon. In agreement with our observation of DNA
re-methylation in hypermethylated promoters, similar findings
have previously been reported in Alu repeats [12,13]. Thus, data
from previous studies and the present one, when taken together,
strongly suggest that DNA re-methylation following demethylating
treatment is a general phenomenon. Although it has not been
investigated in detail, this phenomenon has potential significance
in understanding the epigenetic regulation system and therapeutic
use of DNA methylation inhibitor in treating human cancers and
thus prompted us to further determine its underlying mechanisms.
Figure 1. DNA re-methylation after 5-Aza-dC treatment. (A) Schematic outline of the experimental design. SMMC-7721 cells were treated with
5-Aza-dC at 10 mM for 4 days to induce global demethylation. At Day 4, 5-Aza-dC was removed and cells were replenished with normal culture
medium (DMEM-high glucose, supplemented with 10% FBS). 5-Aza-dC treated cells were allowed to recover in the absence of 5-Aza-dC for an
additional 4 weeks. DLC1 mRNA (B) and protein (C) expression in SMMC-7721 was gradually re-silenced when released from 5-Aza-dC treatment at
Day 4. (D) Consistent with re-silencing of DLC1 expression, SMMC-7221 cells gradually re-acquired DLC1 promoter methylation after removal of 5-Aza-
dC treatment, as revealed by methylation-specific PCR. MSP: methylation-specific PCR, USP, unmethylation-specific PCR. Semi-quantitative analysis
was done by AlphaEaseFC software (Alpha Innotech, San Leandro, CA). (E) In addition to DLC1, gene re-silencing was also observed in multiple
hypermethylated genes, including E-cadherin, GSTP1, uPA and KRT19. In contrast, the expression level of unmethylated tumor suppressor gene
p16
CDKN2A was not affected and remained constant throughout.
doi:10.1371/journal.pone.0016702.g001
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methylation recovery
DNA methylation on CpG dinucleotide is mainly regulated by
the activity of DNMTs. Previous work has demonstrated that de
novo methyltransferase DNMT3B is essential to the re-methylation
of repetitive sequences that are demethylated during the early
stages of embryogenesis [18]. We queried whether the aforemen-
tioned DNA re-methylation was a result of de novo DNA
methylation and mediated by the activity of DNMT3B and
whether other DNMTs were involved. To address this query, we
extended our study with a series of HCT116 cells lines in which
DNMT1, DNMT3B, or both DNMT1 and DNMT3B were deleted
Figure 2. DNMT1 was indispensable for DNA methylation recovery. (A) DLC1 was silenced by DNA hypermethylation in parental HCT116
cells but was substantially expressed in double knockout (DKO) cells. (B) Re-methylation of the DLC1 CpG island in HCT116 cells after 5-Aza-dC
treatment was quantitatively determined by pyrosequencing. DNMT1 knockout (1KO) cells failed to restore DLC1 promoter methylation. In contrast,
DNMT3B knockout cells (3bKO) re-acquired DLC1 promoter methylation as efficiently as parental HCT116 cells. Consistently, 1KO and DKO cells were
unable to re-silence DLC1 gene expression, in contrast to that observed in parental HCT116 and 3bKO cells. Re-silencing of DLC1 mRNA expression in
HCT116 cells was determined by semi-quantitative (C) and real-time quantitative RT-PCR (D). DLC1 expression was normalized against GAPDH and
HPRT, respectively. Data are represented as mean 6 SEM from three independent experiments.
doi:10.1371/journal.pone.0016702.g002
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tumor suppressor gene DLC1 was silenced by DNA hypermethyla-
tion in parental HCT116 cells but was substantially expressed in
double knockout (DKO) cells (Fig. 2A) or re-expressed upon 5-
Aza-dC treatment (Fig. 2C and 2D). Surprisingly, we found that
DNMT3B knockout cells (3bKO), when released from 5-Aza-dC
treatment, re-acquired DLC1 promoter methylation as efficiently
as parental HCT116 cells (Fig. 2B). In contrast, DNMT1 knockout
(1KO) and double knockout (DKO) cells failed to restore DLC1
promoter methylation (Fig. 2B) and consistently, were unable to
re-silence the DLC1 gene expression (Fig. 2C and 2D). Therefore,
our findings clearly indicate that, different from de novo methylation
during the early stages of embryogenesis, DNA methylation
recovery in somatic cells following 5-Aza-dC treatment was
mediated by DNMT1, and not by the conventional de novo DNA
methyltransferase, DNMT3B.
5-Aza-dC-recovered cells remained sensitive to 5-Aza-dC-
induced DNA demethylation.
One major concern regarding the methylation recovery
observed in our system was whether the aforementioned DNA
re-methylation was merely reflecting a selection attributed to the
growth advantage of 5-Aza-dC-resistant cells. To address this
query, we established two independent SMMC-7721 sub-lines
from the pooled 5-Aza-dC-recovered populations (SMMC-7721
RM-P1 and P2). We found that these 5-Aza-dC-recovered sub-
lines, upon 5-Aza-dC treatment as well as during 5-Aza-dC
recovery, responded similarly as their parental SMMC-7721 cells.
Upon re-administration of 5-Aza-dC, hypermethylated genes,
including DLC1, E-cadherin and GSTP1, were successfully re-
expressed in these 5-Aza-dC-recovered cells (Fig 3A). In addition,
these genes were gradually re-silenced upon relief of 5-Aza-dC
treatment (Fig. 3B). Our findings therefore indicate that these
recovered cells remained sensitive to 5-Aza-dC-induced demeth-
ylation and retained the ability of DNA methylation recovery.
Thus, we concluded that the DNA re-methylation after 5-Aza-dC
treatment was not an artifact caused by the expansion of 5-Aza-
dC-resistant sub-populations.
Incomplete DNA re-methylation after 5-Aza-dC treatment
We also observed that, although cancer cells were capable of re-
silencing 5-Aza-dC-demethylated genes, low levels of residual
expression of these normally silenced genes were detected in the
5-Aza-dC-recovered cells (Fig. 1E). We therefore quantitatively
monitored the DNA methylation level of DLC1 gene throughout
the 5-Aza-dC treatment and recovery process. In the SMMC-
7721 cells, using pyrosequencing to quantify the extent of
methylation, approximately 10% of the overall DNA methylation
on the DLC1 CpG islands (on 59UTR and 1
st exon regions) was
permanently lost after 5-Aza-dC treatment (Fig. 4A and 4B). In
fact, we could consistently detect a low level of DLC1 gene
expression in the 5-Aza-dC-recovered cells up to 170 days
(Fig. 4C). This observation implies that the repressive epigenetic
information disturbed by 5-Aza-dC treatment could not be
completely restored. Interestingly, although 5-Aza-dC-recovered
cells retained the ability of DNA methylation recovery upon
repetitive demethylation, the residual gene expression level was
significantly higher in the recovered cells that had undergone
repetitive 5-Aza-dC treatment (Fig. 4D). In light of above findings,
we speculated that multiple administrations may be required to
ensure complete re-activation of tumor suppressor genes following
treatment with 5-Aza-dC and perhaps other DNA methylation
inhibitors. This may have implications on the administration and
efficacy of DNA methylation inhibitors in cancer treatment.
Consistent enrichment of H3K4-tri-methylation among
heterogeneous re-methylated DLC1 locus ruled out the
possibility of stochastic DNA demethylation escape.
By investigating a series of clonally expanded 5-Aza-dC-
recovered cells, we found substantial gene expression as a result
of incomplete DNA methylation recovery in multiple 5-Aza-dC-
recovered clones. The genes showed incomplete DNA re-silencing
including DLC1, E-Cadherin, and GSTP1, but exhibited a
differential pattern among individual clones (i.e. RM-C6 and
C13 for DLC1; RM-C5, C12 and C13 for E-Cadherin and RM-C11
and C13 for GSTP1, respectively) (Fig. 5A and 5B). Hence, the
incomplete DNA methylation recovery was apparently heteroge-
Figure 3. 5-Aza-dC-recovered cells were sensitive to 5-Aza-dC induced derepression. To exclude the potential artifact of DNA re-
methylation caused by 5-Aza-dC-resistant cells, two 5-Aza-dC-recovered sub-lines (SMMC-7721 RM-P1 and P2) were established from pooled 5-Aza-
dC-recovered population of SMMC-7721. (A) The expression of re-methylated tumor suppressor genes, DLC1, E-Cadherin and GSTP1, could
successfully be activated once again in these recovered cells by re-administration of 5-Aza-dC. M, Mock; Az, 5-Aza-dC. (B) 5-Aza-dC-recovered cells
retained the ability to re-silence DLC1 after being released from 5-Aza-dC treatment. These data indicate that 5-Aza-dC-recovered cells remained
sensitive to 5-aza-dC-induced derepression and re-silencing Thus, ruled out the possibility of growth selection artifact caused by the expansion of5 -
Aza-dC-resistant sub-populations.
doi:10.1371/journal.pone.0016702.g003
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provided an explanation accounting for the low residual gene
expression seen in 5-Aza-dC-recovered cells. However it also
raised the possibility that DNA methylation recovery might be an
artifact of selection advantage for cells that occasionally escaped
from DNA demethylation during 5-Aza-dC treatment. To exclude
this possibility, we compared the H3K4 tri-methylation level on
the DLC1 locus among the 5-Aza-dC-recovered clones with
reference to their DNA methylation status. It has been reported
that H3K4 methylation could be enriched upon 5-Aza-dC
treatment, likely a secondary event following the promoter
demethylation and gene re-expression [19,20,21]. Consistent with
this notion, in SMMC-7721 cells we also observed a remarkable
enrichment of H3K4 methylation at DLC1 locus upon 5-Aza-dC
treatment (Figure S4). Therefore, H3K4 methylation level could
be used as a trace mark for locus that had undergone DNA
Figure 4. Incomplete DNA methylation recovery after 5-Aza-dC treatment. DLC1 CpG island methylation and mRNA expression in SMMC-
7721 cells during the 5-Aza-dC treatment (Day 0 to Day 4) and recovery (Day 4 to Day 170) were determined. Approximately 10% of the overall DNA
methylation on the DLC1 59UTR (A) and 1
st exon (B) was permanently lost after 5-Aza-dC treatment. Quantitatively analysis was done by
pyrosequencing, and the average methylation of 10 and 8 CpG dinucleotides on 59UTR and first exon, respectively, was obtained from three
independent experiments and is presented as mean 6 SEM. (C). Consistently, a low level of residual DLC1 gene expression in 5-Aza-dC-recovered cells
could be detected in SMMC-7721 cells (up to 170 days). (D). Residual DLC1 gene expression was significantly higher (P=0.0010, t-test) in the 5-Aza-
dC-recovered cells that were re-administered with 5-Aza-dC (comparing day 16 and day 129, i.e. 12 days after 1
st and 2
nd 5-Aza-dC treatment),
suggesting that multiple administrations may be required to ensure complete demethylation of tumor suppressor genes following treatment with 5-
Aza-dC. Opened circles and rectangles indicate the start and the end of 5-Aza-dC treatment, respectively (Mean 6 SEM, N=4).
doi:10.1371/journal.pone.0016702.g004
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and two DLC1-hypomethylated clones (RM-C6 and C13) were
selected for investigation. Using chromatin immunoprecipitation
(ChIP) assay, we found that regardless of their status of DNA
methylation recovery and gene expression level, H3K4 tri-
methylation (H3K4-me3) was considerably enriched on DLC1
promoter in all 5-Aza-dC-recovered clones when compared with
their parental SMMC-7721 cells (Fig. 5C). This finding indicate
that the DLC1 locus in all 5-Aza-dC-recovered cells tested had
undergone DNA demethylation during 5-Aza-dC treatment and
thus ruled out the possibility of growth selection of stochastic
demethylation escaped cells.
Figure 5. Differential histone modifications associated with heterogeneous DNA methylation recovery. Individual 5-Aza-dC-recovered
clones (SMMC-RM-C3 to C13) were established by clonal expansion of SMMC-7721 cells after 5-Aza-dC treatment. (A) mRNA expression of normally
hypermethylated tumor suppressor genes (DLC1, E-Cadherin and GSTP1) in each of the 5-Aza-dC-recovered clones was determined by semi-
quantitative RT-PCR. (B) Methylation of DLC1 gene in individual 5-Aza-dC-recovered clones was determined by methylation-specific PCR. Incomplete
gene re-silencing of DLC1, E-Cadherin, and GSTP1 was found in multiple 5-Aza-dC-recovered clones, but the genes involved varied among individual
clones. (C) H3K4 tri-methylation (H3K4-me3) was considerably enriched on DLC1 promoter in all 5-Aza-dC-recovered clones when compared with
their parental SMMC-7721 cells, indicating that the DLC1 locus in all 5-Aza-dC-recovered clones tested had undergone DNA demethylation during 5-
Aza-dC treatment. (D) H3K9 tri-methylation (H3K9-me3) was preserved in DLC1 re-methylated clones, whereas it was significantly reduced in the DLC1
hypomethylated clones (i.e. RM-C6 and C13). (E) H3K27-me3 level was significantly enriched on the DLC1 promoter exclusively in those re-methylated
clones (RM-C4 and C11), whereas the H3K27-me3 level remained unchanged in those hypomethylated clones (RM-C6 and C13). These findings
suggest that preserved H3K9-me and enrichment of H3K27-me3 level were associated with DNA methylation recovery mediated by DNMT1. Histone
modifications on DLC1 promoter region were revealed by ChIP assay using antibody against H3K4-me3, H3K9-me3 and H3K27-me3, respectively.
Quantitative data were obtained with real-time PCR and are presented as ‘‘Relative enrichment’’ (mean 6 SEM). Data were obtained from three
independent repeats.
doi:10.1371/journal.pone.0016702.g005
DNA Methylation Recovery
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DNA methylation recovery
The heterogeneous pattern of DNA methylation recovery
strongly suggested that the repressive epigenetic information
disturbed by 5-Aza-dC treatment might not be completely
restored. Having excluded the possibility of growth selection of
cells which might have stochastically escaped demethylation, we
therefore considered another possible explanation that differential
DNA methylation recovery could be determined by local histone
modification marks. We hypothesized that stable transcriptional
repressive histone modifications might be preserved in those re-
methylated locus and contribute to the DNA methylation
recovery. Herein, we found that in contrast to H3K4 methylation,
H3K9 tri-methylation (H3K9-me3) was preserved in DLC1 re-
methylated clones, whereas it was significantly reduced in the
DLC1 hypomethylated clones (i.e. RM-C6 and C13) (Fig. 5D). The
concurrence of the loss of H3K9-me3 and the absence of DNA re-
methylation in these expanded clones implicate a crucial role of
H3K9-me3 in DNA methylation recovery. Next, we queried
whether another stable repressive histone modification, H3K27
tri-methylation (H3K27-me3), might also play a role in DNA
methylation recovery. In this regard, we observed a notable
increase in H3K27-me3 level on the DLC1 promoter exclusively in
those re-methylated clones (RM-C4 and C11), whereas the
H3K27-me3 level remained unchanged in those hypomethylated
clones (RM-C6 and C13) as compared with their parental
SMMC-7721 cells (Fig. 5E). Our findings therefore implied that
increased H3K27-me3 level was associated with DNA methylation
recovery mediated by DNMT1.
Discussion
The contribution of epigenetic changes in tumor suppressor
gene inactivation and human carcinogenesis has received much
attention in the past years [4,22,23]. Among all epigenetic
alterations, DNA hypermethylation on the promoter region of
tumor suppressor genes probably is most well characterized.
Unlike genetic alterations such as gene mutation and chromo-
somal amplification/deletion, DNA hypermethylation is consid-
ered as a reversible process and this has therefore rendered the
basis of cancer epigenetic therapy [10,24,25,26]. Mounting pre-
clinical evidence has demonstrated that treatment of DNA
methylation inhibitors can successfully restore the expression of
hypermethylated tumor suppressor genes and inhibit cancer cell
growth. However, recent studies have indicated that those
demethylated genes or loci can undergo re-methylation once
released from demethylating treatment [25,26]. This observation
has added new insight towards the better understanding of the
complicated epigenetic regulation system and may have potential
implication for clinical use of DNA methylation inhibitors in
cancer treatment. However, the underlying mechanisms of this
DNA methylation recovery process remain largely unknown and
further investigation is much wanted.
In this study, we employed the commonly used DNA
methylation inhibitor, 5-Aza-dC, to induce global DNA demeth-
ylation in human cancer cells. Consistent with previous studies, we
observed that multiple DNA hypermethylated genes were robustly
reactivated by 5-Aza-dC [27,28]. However, these genes gradually
underwent DNA re-methylation and were re-silenced once
released from the treatment. Apparently, gene re-silencing is a
genome-wide phenomenon. We showed that resilencing was not
only found in well characterized tumor suppressor genes but also
in those normally hypermethylated oncogenes and tissue specific
genes. Based on our current knowledge about DNA methylation, it
is reasonable to deduce that DNA methyltransferases may be
involved in the DNA methylation recovery process. Although it
has been hypothesized that de novo methyltransferase DNMT3A or
DNMT3B might be the major player, this notion was not
supported by our experimental data. With the widely used DNMT
knock-out HCT116 cell models, we have shown that loss of
DNMT1 alone was sufficient to abolish the DNA re-methylation.
In contrast, loss of DNMT3B had no detectable effect on the DNA
methylation recovery process. Similar finding has also been
previously reported by Egger and colleagues [29].
It is important to note that global DNA methylation level was
only slightly reduced in this particular DNMT1 KO cell line,
indicating that its ‘‘maintenance’’ methyltransferase activity was
basically preserved [14,15]. The ‘‘maintenance’’ methyltransferase
activity in this DNMT1 KO cell line could at least be partially
explained by the recently identified truncated DNMT1 protein,
which is an alternatively splicing product and could bypass the
somatic deletion of DNMT1 gene in this HCT116 cell line [29,30].
This truncated DNMT1 protein retains its catalytic activity but
lacks the PCNA-binding domain [31]. Recent work has shown
that the PCNA-binding domain was essential in recruiting
DNMT1 to DNA repair sites immediately after UV irradiation
[32]. It is likely that the PCNA-binding domain may also
important for this DNMT1-mediated DNA methylation recovery.
Therefore lack of the PCNA-binding domain in this truncated
DNMT1 may provide an explanation to account for the loss of
DNA methylation recovery function in this DNMT1 KO cell line,
despite the fact that the ‘‘maintenance’’ methylation was not
significantly affected. Based on above findings, we propose that
DNMT1 may possess two independent functions in maintaining
DNA methylation integrity: on one hand, DNMT1 is responsible
for maintaining DNA methylation pattern in the newly synthe-
sized DNA strand after DNA replication; on the other, DNMT1 is
also involved in DNA methylation recovery probably via its de novo
methyltransferase activity [33].
In this study, we noticed that although the majority of 5-Aza-dC
treated cells underwent DNA re-methylation upon drug relief, the
DNA methylation recovery was however not a perfect process.
Among the ten 5-Aza-dC recovery clones established from
SMMC-7721 cells, two of them failed to re-acquire their DNA
methylation level at DLC1 promoter that was disturbed by 5-Aza-
dC treatment. This incomplete DNA methylation recovery
accounted for approximately 10% loss of overall DNA methyla-
tion level and consequently led to the presence of a low level of
gene expression in 5-Aza-dC-recovered population. It is well
documented that both unmethylated DNA and H3K4 hyper-
methylation are associated with transcriptionally active euchro-
matin, whereas densely methylated DNA and H3K9 hypermethy-
lation are frequently found in transcriptionally repressive
heterochromatin, suggesting that the two major layers of
epigenetic regulation, DNA methylation and histone modification,
are in fact functionally linked [22,34,35]. We therefore tested
whether this DNA methylation recovery mediated by DNMT1
would be regulated by local repressive histone modifications. It has
previously been shown that 5-Aza-dC treatment resulted in loss of
H3K9-methylation and enrichment of both H3K9 acetylation and
H3K4-methylation. These histone modifications were accompa-
nied with DNA demethylation and re-expression of hMLH1 gene
in colon cancer cell lines [19]. Since currently there is no evidence
indicating that 5-Aza-dC may have direct effect on histone
modification, these histone modification changes likely occurred as
a secondary event upon DNA demethylation and together
facilitated the reactivation of epigenetic silenced genes. Indeed,
we observed a consistent enrichment of H3K4 methylation at the
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recovered clones regardless of their DNA re-methylation status.
This H3K4 methylation enrichment was consistent with those of
the previous reports [19,36] and indicated that DLC1 promoter in
all 5-Aza-dC-recovered clones had underwent DNA demethyla-
tion during 5-Aza-dC treatment.
Interestingly, previous study had indicated that the stable
repressive marks (H3K9-me3 and H3K27-me3) remained un-
changed upon 5-Aza-dC treatment. Inferred from this observa-
tion, it has been speculated that these stable repressive marks may
be related to DNA methylation recovery [36]. However, two most
recent studies reported that 5-Aza-dC treatment converted the
transcriptional repressive histone modifications pattern to tran-
scriptional active marks [20,21]. To explore the role of repressive
histone modifications on DNA methylation recovery and gene re-
silencing, we compared the H3K9-me3 levels between 5-Aza-dC-
recovered clones with or without DNA re-methylation. Our data
showed that H3K9-me3 level was preserved in the majority of
5-Aza-dC-recovered clones that had exhibited DNA re-methyla-
tion at DLC1 promoter and gene re-repression (as in RM-C4 and
C11 clones). In contrast, we observed a significant decrease of
H3K9-me3 level in the 5-Aza-dC-recovered clones that showed no
DNA re-methylation. Our findings suggest that loss of H3K9-me3
caused by 5-Aza-dC treatment may impair the DNA re-
methylation process. Consistent with this notion, mutation of K9
residue of histone 3 or H3K9 specific histone methyltransferase
was found to induce gross DNA hypomethylation [37,38].
Therefore, it is reasonable to believe that H3K9-me3 is essential
for DNA methylation recovery. We reason that DNA demethyl-
ation caused by 5-Aza-dC treatment may eventually lead to re-
establishment of local histone modifications and chromatin
structure. Once this happens, the repressive epigenetic status
may not be completely restored by the DNA methylation recovery
system.
Interestingly, we also found a remarkable increase of H3K27-
me3 at the DLC1 promoter of 5-Aza-dC-recovered clones.
H3K27-me3 enrichment was exclusively detected in those re-
methylated clones whereas it remained unchanged in the two
clones that showed no DNA re-methylation. This observation
suggests that H3K27-me3 may also play a role in DNA
methylation recovery. It is known that H3K27-me3 is catalyzed
by a polycomb group protein EZH2 [39]. EZH2 is physically
associated with human DNMT1, and depletion of EZH2 results in
significant reduction of DNA methylation on the promoter region
of MYT1 gene [9]. More recently, significant enrichment of
H3K27 methylation has been found in hypermethylated genes in
human cancers and implicated in de novo DNA methylation
[40,41,42]. All these lines of evidence suggest that the persistent
H3K9-me3 and increased H3K27-me3 may serve as an initial
signature for the recruitment of DNMT1 to demethylated loci and
execute its DNA methylation recovery function.
The major concern of DNA re-methylation observed in
previous studies is whether this phenomenon was merely reflecting
an artifact ensued from growth selection rather than a meaningful
biological mechanism. Herein, we have provided several lines of
evidence to support the presence of DNA methylation recovery
system in mammalian cells. First, DNA methylation recovery was
consistently observed in the different cell lines that expressed
functional DNMT1 but was completely abolished in the DNMT1
knock-out cell lines (HCT116 1KO and DKO). If DNA re-
methylation were merely due to growth selection, this selection
artifact should have applied to all cell lines tested regardless of
their DNMT1 status. However, as discussed above, the function of
DNMT1 was apparently involved in this DNA re-methylation
process and thus provided mechanistic evidence to the DNA
methylation recovery system. Second, 5-Aza-dC-recovered cells
were as sensitive to 5-Aza-dC treatment as their parental cells,
indicating that DNA re-methylation was unlikely caused by the
expansion of 5-Aza-dC-resistant sub-populations. Third, the
consistent enrichment of H3K4 me3 level at normally DNA
hypermethylated loci provided clear evidence supporting the
presence of DNA demethylation during the 5-Aza-dC treatment
and excluded the involvement of stochastic DNA demethylation
escape. The above lines of evidence, when taken together, strongly
suggest that mammalian cells possess a bona fide DNA
methylation recovery system and exclude the possibility of growth
selection artifact. The biological significance of the aforesaid DNA
methylation recovery system needs to be further investigated.
Inferring from the observation that homologous deletion of
DNMT1 significantly abolished the colony forming ability of
HCT116 cells after 5-Aza-dC treatment (unpublished observa-
tion), we speculate that DNMT1-mediated DNA methylation
recovery may have an important role in protecting the cells against
unphysiological demethylation.
Our present findings on the DNA methylation recovery system
also have potential implication in the clinical use of DNA
methylation inhibitors in cancer treatment. Two major DNA
methylation inhibitors, azacytidine (5-Aza-cytidine) and decitabine
(5-Aza-deoxycytidine) have been approved by Food and Drug
Administration (FDA) for treating myelodysplastic syndrome and
have shown promising anti-cancer effects in various myeloid
malignancies in recent clinical trials. However, the clinical
outcome of these drugs in treating solid tumors was not totally
satisfactory [26]. One possible reason is attributed to the instability
of DNA methylation inhibitors in physiological conditions in that
they became undetectable within a short time after administration
[43,44]. The 5-Aza-dC relief approach used in this system actually
mimics the consequence of rapid elimination of DNA methylation
inhibitors in clinical situation. In this scenario, cancer cells will
take advantage of DNA methylation recovery system, resulting in
re-silencing of DNA hypermethylated genes. In this regard, the
efficacy of DNA methylation inhibitors in cancer treatment could
be significantly improved if the DNA methylation recovery system
could be suppressed or minimized. We have shown that, despite
the finding that cancer cells possess DNA methylation recovery
system, DNA methylation disturbed by 5-Aza-dC treatment could
not be completely restored. More importantly, DNA demethyla-
tion accumulated upon repetitive treatment, likely attributable to
the re-establishment of local histone modifications as discussed
above. Thus our findings have provided experimental evidence to
support the rationale of repetitive administration in cancer
treatment in order to maximize the demethylating effect.
Moreover, in light of the essential roles of H3K9-me3 and
H3K27-me3 in DNMT1-mediated DNA methylation recovery
demonstrated in this study, it can be inferred that combined
treatment of DNA methylation inhibitors with SUV39H1 (H3K9-
me3 specific histone methyltransferase) or EZH2 (H3K27-me3
specific histone methyltransferase) inhibitors may have potential
advantage in suppressing this DNA methylation recovery and
achieving enduring DNA demethylation. Small molecular inhib-
itors that specifically target SUV39H1 and EZH2 have been
discovered recently [45,46]. Pioneering studies have shown that
both SUV39H1 and EZH2 inhibitors exhibited cancer suppressive
effects in vitro [45,46,47]. We anticipate that their toxicity, anti-
cancer activity and therapeutic potential will be extensively
evaluated in the foreseeable future. It would be interesting to test
whether such combined treatments may improve the clinical
outcome of our current epigenetic therapy protocol. In summary,
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towards the DNA methylation recovery system and may have
potential implications for the development of new epigenetic
therapeutic strategy.
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Figure S1 Position of primers used in expression and
epigenetic studies. Positions indicated above are reference to
the putative DLC1 transcription start site (TSS) according to the
Genebank database NM_006094.
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Figure S2 DLC1 methylation in normal liver cell line
(MIHA) and liver cancer cell line (SMMC-7721). DNA
methylation at +45 to +336 position of DLC1 gene was analyzed
by bisulfite DNA sequencing. PCR products were cloned into
TOPO TA Cloning vector (Invitrogen) and five clones from each
sample were sequenced. Open circle: Unmethylated CpG site;
Closed circle: methylated CpG dinucleotide.
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Figure S3 Re-silencing of DLC1 and E-Cadherin in HeLa
cell after 5-Aza-dC treatment. HeLa cell was treated with
5 uM 5-Aza-dC for 96 hrs (Day 4) and allowed to recover in drug
free culture medium (Day 8 and Day 12). Expression of
hypermethylated genes, DLC1 and E-Cadherin were monitored by
semi-quantitative RT-PCR. Unmethylated GSTP1 gene and a
house keeping gene, GAPDH were served as controls.
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Figure S4 Enrichment of H3K4-me3 in DLC1 promoter
upon 5-Aza-dC treatment. SMMC-7721 was treated with
10 uM 5-Aza-dC for 96 hrs. ChIP assay was performed with
specific antibody against H3K4-tri-methylation (Upstate). Relative
enrichment of H3K4-me3 in 5-Aza-dC treated cells was
determined by Q-PCR.
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